Tango Therapeutics, Inc.
TNGX
Rankning i aktier
#4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aktiekurs
$27.18
Senast synkroniserad: 2026-07-31
Marknadsvärde
$3.38B
Förändring (1 dag)
-1.41%
Förändring (1 år)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Vinst för Tango Therapeutics, Inc. (TNGX)
Vinst i Jun 2026 TTM: $-123.78M
Enligt de senaste finansiella rapporterna från Tango Therapeutics, Inc. är företagets nuvarande vinst $-123.78M. År 2023 hade företaget en vinst på $-101.61M, en ökning jämfört med vinsten år 2022 som var $-108.12M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Tango Therapeutics, Inc. från 2019 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-123.78M | -4.85% |
| 2024 | $-130.09M | 28.03% |
| 2023 | $-101.61M | -6.02% |
| 2022 | $-108.12M | 86.60% |
| 2021 | $-57.94M | 11.49% |
| 2020 | $-51.97M | 268.73% |
| 2019 | $-14.10M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | -4,361.41% |
US
|
|
| $-3.09B | 2,393.88% |
US
|
|
| $-4.02B | 3,144.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,675.86% |
NL
|
